#USA #Boston #Drug Delivery #PRIME NEXUS™ #Portal Instruments

Portal Instruments Announces Development Agreement for PRIME NEXUS™

Portal Instruments, a pioneer in the medical device sector, has made significant strides in enhancing drug delivery technologies. Recently, the company announced a multi-million dollar agreement with a leading biotech partner to advance its groundbreaking autoinjector, PRIME NEXUS™, towards clinical readiness, aiming for a 2027 launch.

What Makes PRIME NEXUS™ Innovative?

The PRIME NEXUS™ is designed as a large-volume, reusable autoinjector intended to modernize the way medications, especially biologics, are administered. Unlike conventional disposable autoinjectors that can struggle with larger, more viscous drugs, PRIME NEXUS™ utilizes advanced electromechanical technology. This allows for the accommodation of various primary containers, including 1mL, 2mL, and now 5mL prefilled syringes (PFS), ensuring that injections are efficient and consistent, even with complex formulations.

A Sustainable Solution for Healthcare

With the medical community facing mounting pressure due to the environmental impact of single-use devices, the PRIME NEXUS™ emerges as a solution that prioritizes sustainability. Traditional autoinjectors contribute to massive amounts of waste, with hundreds of millions discarded annually. The reusable design of PRIME NEXUS™ not only reduces material waste but also lowers the cost per injection, making it especially appealing for high-volume chronic therapies.

Key Developments and Future Goals

Portal Instruments aims to finalize the industrialization of PRIME NEXUS™ by the end of 2026, which includes thorough verification and validation testing. The partnership with the biotech company is seen as a pivotal moment for PRIME NEXUS™, transitioning it from the development phase to clinical deployment. As noted by Steven Kaufman, Chief Commercial Officer of Portal, successful feasibility programs with large pharmaceutical partners have demonstrated the demand for scalable and high-performance delivery systems.

Enhancing Patient Experience and Outcomes

The ultimate goal of this innovative endeavor is to enhance the patient experience. By providing reliable and efficient drug delivery, PRIME NEXUS™ is set to improve patient adherence to treatment regimens, thereby improving overall clinical outcomes. The reusable mechanism and simplified disposable cassette are designed with the user in mind, ensuring that the experience is both straightforward and effective for patients.

Looking Ahead: The Future of Drug Delivery

The collaboration between Portal Instruments and the biotech firm not only emphasizes the technical capabilities of PRIME NEXUS™ but also opens up pathways for comprehensive industrialization. Daniel Diezi, Board Member of Portal Instruments, highlighted the platform's potential, stating it is engineered for reliable clinical and commercial supply. This forward-thinking approach is crucial for the introduction of next-generation delivery systems that can be efficiently brought to market.

Dr. Patrick Anquetil, Founder and CEO of Portal Instruments, summed it up well: "Our vision has always aimed to expand the possibilities in subcutaneous drug delivery." With PRIME NEXUS™, the company not only hopes to revolutionize drug delivery but also to facilitate continuous innovation and sustainability in the pharmaceutical landscape.

Conclusion

The future of drug delivery appears bright with the advancement of technologies like PRIME NEXUS™. This initiative by Portal Instruments marks a significant shift towards reusable, efficient, and patient-friendly solutions in healthcare, catering to the evolving needs of both pharmaceutical companies and patients alike.

For more information about Portal Instruments and their innovative drug delivery platforms, visit Portal Instruments.